| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Arrowhead Pharmaceuticals, Inc. (ARWR) has 12 insiders with recent SEC Form 4 filings, including 0 buys and 11 sells. ARWR is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 3.79M | $311.00M | - | |
| COO | 473.3K | $38.81M | - | |
| Other | 227.0K | $18.61M | - | |
| CFO | 162.9K | $13.36M | - | |
| Dir | 123.1K | $10.09M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Feb 5, 2019 | Given Bruce D | Chief Operating Officer | Sell | 22,500 | $14.48 | $325,800.00 | -2.6% | |
| Feb 1, 2019 | Given Bruce D | Chief Operating Officer | Sell | 28,500 | $13.85 | $394,725.00 | -3.2% | |
| Jan 23, 2019 | Given Bruce D | Chief Operating Officer | Sell | 169,500 | $13.54 | $2,295,805.00 | -8.5% | |
| Jan 22, 2019 | Given Douglas B66 | Director | Sell | 3,000 | $13.58 | $40,740.00 | -1.7% | |
| Jan 18, 2019 | O'Brien Patrick76 | General Counsel | Sell | 72,000 | $14.43 | $1,038,960.00 | -23.6% | |
| Jan 17, 2019 | Myszkowski Kenneth Allen68 | Chief Financial Officer | Sell | 81,875 | $14.55 | $1,191,281.25 | -21.1% | |
| Jan 14, 2019 | Given Bruce D | Chief Operating Officer | Sale+OE | 42,666 | $14.40 | $614,390.40 | -3.8% | |
| Jan 14, 2019 | Li Zhen | Snr. VP, Chem And Non-clin Dev | Sell | 40,500 | $14.34 | $580,770.00 | -16.7% | |
| Jan 11, 2019 | Waddill William D.50 | Director | Sell | 8,500 | $14.77 | $125,545.00 | -15.5% | |
| Jan 2, 2019 | Myszkowski Kenneth Allen68 | Chief Financial Officer | Sell | 8,333 | $11.98 | $99,829.34 | -2.1% |